Aspirin Reduces Liver Fat in Clinical Trial of the Most Common Cause of Chronic Liver Disease
Results warrant additional studies into the health benefits of aspirin for patients with metabolic dysfunction–associated steatotic liver disease.
Department of Medicine
Contact Information
165 Cambridge Street
Suite 302
Boston,
MA
02114
Phone: 617-726-7584
Fax: 617-724-1122
Email: skalim@mgh.harvard.edu
My research focuses on understanding the fundamental causes of the excess morbidity and mortality seen in patients with chronic and end-stage kidney disease in an effort to develop new targeted therapies. We have linked a protein modification known as carbamylation to several adverse outcomes such as resistance to erythropoietin and mortality in patients with kidney disease. Similarly, using high throughput screening, we have identified a number of novel metabolite derangements associated with cardiovascular disease in dialysis patients. We are now studying ways to correct these metabolic disturbances and determine, through clinical trials, if doing so results in improved patient outcomes.
Every day, our clinicians and scientists chart new terrain in biomedical research to treat and prevent human disease and advance patient care.
Your support of Nephrology helps us provide the best possible care today and expand what will be possible tomorrow.
We offer innovative, high-quality medical care, trains future medical leaders, and produces research that advances science and improves care.
Results warrant additional studies into the health benefits of aspirin for patients with metabolic dysfunction–associated steatotic liver disease.
Researchers have identified numerous genetic clusters that may help explain why people with type 2 diabetes have different clinical presentations.
We reached out to investigators at Massachusetts General Hospital and asked them to give us one science-backed action people can take to improve their heart health.
In a nationally representative of US adults with self-reported chronic liver disease (CLD), approximately 308,000 (6%) identified delaying medical care due to transportation barriers.
In this 12-month, placebo-controlled, randomized clinical trial of 26 well-treated persons with HIV without known CVD, eplerenone was associated with a significant reduction in arterial inflammation.
Blocking reductive stress in the liver may benefit people with conditions such as obesity and fatty liver disease.
The Division of Nephrology at Massachusetts General Hospital is a leading provider of services for patients with kidney disease, including diagnosis and management of kidney diseases and medical management of renal transplantation.